Important Patent Extension government data with business impact

Notice 16 Jun 2025 compliance, pharmaceuticals, fda, regulatory review, patent extension, befortus

💊FDA Notice on Regulatory Review and Patent Extension for BEYFORTUS

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEYFORTUS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More

Notice 16 Jun 2025 regulatory compliance, healthcare, pharmaceuticals, fda, biotechnology, patent extension

💊FDA's Patent Extension Review for ROLVEDON and Its Business Impact

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROLVEDON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More

Notice 16 Jun 2025 healthcare, fda, drug regulation, patent extension, vafseo

💊FDA Notice on Patent Extension for VAFSEO Drug Regulations

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VAFSEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 16 Jun 2025 pharmaceuticals, fda, regulatory review, health, patent extension, voydeya

💊FDA Determines Regulatory Review Period for VOYDEYA Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOYDEYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 16 Jun 2025 healthcare, regulation, pharmaceuticals, fda, drug approval, patent extension

💊FDA's Determination of Regulatory Review Period for RIVFLOZA

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RIVFLOZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 16 Jun 2025 regulatory compliance, health care, fda, drug development, pharmaceutical industry, patent extension, briumvi

💊FDA Notice on BRIUMVI Patent Extension Implications

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIUMVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More

Notice 16 Jun 2025 regulatory compliance, healthcare, fda, medical devices, patent extension

💉FDA's Regulatory Review Period Determination for AVEIR VR System

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVEIR VR Leadless System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.

Learn More

Notice 16 Jun 2025 regulations, business strategy, pharmaceuticals, fda, patent extension

💊FDA Determination of Regulatory Review Period for ZEVTERA Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEVTERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 16 Jun 2025 regulation, fda, pharmaceutical, patent extension, xolremdi, human drug products

💊FDA Notice on Regulatory Review Period for XOLREMDI Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XOLREMDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 16 Jun 2025 fda, regulatory review, pharmaceutical, patent extension, vowst

💊FDA Issues Regulatory Review Period for VOWST Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOWST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More